282 related articles for article (PubMed ID: 20652724)
1. Combination of 6-thioguanine, capecitabine, and celecoxib with temozolomide or lomustine for recurrent high-grade glioma.
Walbert T; Gilbert MR; Groves MD; Puduvalli VK; Yung WK; Conrad CA; Bobustuc GC; Colman H; Hsu SH; Bekele BN; Qiao W; Levin VA
J Neurooncol; 2011 Apr; 102(2):273-80. PubMed ID: 20652724
[TBL] [Abstract][Full Text] [Related]
2. Procarbazine, lomustine and vincristine for recurrent high-grade glioma.
Parasramka S; Talari G; Rosenfeld M; Guo J; Villano JL
Cochrane Database Syst Rev; 2017 Jul; 7(7):CD011773. PubMed ID: 28744879
[TBL] [Abstract][Full Text] [Related]
3. Second-line chemotherapy with temozolomide in recurrent oligodendroglioma after PCV (procarbazine, lomustine and vincristine) chemotherapy: EORTC Brain Tumor Group phase II study 26972.
van den Bent MJ; Chinot O; Boogerd W; Bravo Marques J; Taphoorn MJ; Kros JM; van der Rijt CC; Vecht CJ; De Beule N; Baron B
Ann Oncol; 2003 Apr; 14(4):599-602. PubMed ID: 12649108
[TBL] [Abstract][Full Text] [Related]
4. Clinical benefit in recurrent glioblastoma from adjuvant NovoTTF-100A and TCCC after temozolomide and bevacizumab failure: a preliminary observation.
Wong ET; Lok E; Swanson KD
Cancer Med; 2015 Mar; 4(3):383-91. PubMed ID: 25620708
[TBL] [Abstract][Full Text] [Related]
5. Procarbazine and CCNU Chemotherapy for Recurrent Glioblastoma with MGMT Promoter Methylation.
Kim SH; Yoo H; Chang JH; Kim CY; Chung DS; Kim SH; Park SH; Lee YS; Yang SH
J Korean Med Sci; 2018 Jun; 33(24):e167. PubMed ID: 29892208
[TBL] [Abstract][Full Text] [Related]
6. Efficacy of temozolomide treatment in patients with high-grade glioma.
Oshiro S; Tsugu H; Komatsu F; Ohmura T; Ohta M; Sakamoto S; Fukushima T; Inoue T
Anticancer Res; 2009 Mar; 29(3):911-7. PubMed ID: 19414327
[TBL] [Abstract][Full Text] [Related]
7. Combination of 6-thioguanine, procarbazine, lomustine, and hydroxyurea for patients with recurrent malignant gliomas.
Kyritsis AP; Yung WK; Jaeckle KA; Bruner J; Gleason MJ; Ictech SE; Flowers A; Levin VA
Neurosurgery; 1996 Nov; 39(5):921-6. PubMed ID: 8905746
[TBL] [Abstract][Full Text] [Related]
8. Rechallenge with temozolomide in patients with recurrent gliomas.
Wick A; Pascher C; Wick W; Jauch T; Weller M; Bogdahn U; Hau P
J Neurol; 2009 May; 256(5):734-41. PubMed ID: 19240962
[TBL] [Abstract][Full Text] [Related]
9. A multicenter phase II study of temozolomide plus disulfiram and copper for recurrent temozolomide-resistant glioblastoma.
Huang J; Chaudhary R; Cohen AL; Fink K; Goldlust S; Boockvar J; Chinnaiyan P; Wan L; Marcus S; Campian JL
J Neurooncol; 2019 May; 142(3):537-544. PubMed ID: 30771200
[TBL] [Abstract][Full Text] [Related]
10. Phase II study of temozolomide, thalidomide, and celecoxib for newly diagnosed glioblastoma in adults.
Kesari S; Schiff D; Henson JW; Muzikansky A; Gigas DC; Doherty L; Batchelor TT; Longtine JA; Ligon KL; Weaver S; Laforme A; Ramakrishna N; Black PM; Drappatz J; Ciampa A; Folkman J; Kieran M; Wen PY
Neuro Oncol; 2008 Jun; 10(3):300-8. PubMed ID: 18403492
[TBL] [Abstract][Full Text] [Related]
11. Phase II trial of lomustine plus temozolomide chemotherapy in addition to radiotherapy in newly diagnosed glioblastoma: UKT-03.
Herrlinger U; Rieger J; Koch D; Loeser S; Blaschke B; Kortmann RD; Steinbach JP; Hundsberger T; Wick W; Meyermann R; Tan TC; Sommer C; Bamberg M; Reifenberger G; Weller M
J Clin Oncol; 2006 Sep; 24(27):4412-7. PubMed ID: 16983109
[TBL] [Abstract][Full Text] [Related]
12. Sunitinib Malate plus Lomustine for Patients with Temozolomide-refractory Recurrent Anaplastic or Low-grade Glioma.
Duerinck J; Du Four S; Sander W; Van Binst AM; Everaert H; Michotte A; Hau P; Neyns B
Anticancer Res; 2015 Oct; 35(10):5551-7. PubMed ID: 26408725
[TBL] [Abstract][Full Text] [Related]
13. Two phase II trials of temozolomide with interferon-alpha2b (pegylated and non-pegylated) in patients with recurrent glioblastoma multiforme.
Groves MD; Puduvalli VK; Gilbert MR; Levin VA; Conrad CA; Liu VH; Hunter K; Meyers C; Hess KR; Alfred Yung WK
Br J Cancer; 2009 Aug; 101(4):615-20. PubMed ID: 19672263
[TBL] [Abstract][Full Text] [Related]
14. Temozolomide versus procarbazine, lomustine, and vincristine in recurrent high-grade glioma.
Brada M; Stenning S; Gabe R; Thompson LC; Levy D; Rampling R; Erridge S; Saran F; Gattamaneni R; Hopkins K; Beall S; Collins VP; Lee SM
J Clin Oncol; 2010 Oct; 28(30):4601-8. PubMed ID: 20855843
[TBL] [Abstract][Full Text] [Related]
15. Phase II trial of irinotecan plus celecoxib in adults with recurrent malignant glioma.
Reardon DA; Quinn JA; Vredenburgh J; Rich JN; Gururangan S; Badruddoja M; Herndon JE; Dowell JM; Friedman AH; Friedman HS
Cancer; 2005 Jan; 103(2):329-38. PubMed ID: 15558802
[TBL] [Abstract][Full Text] [Related]
16. Retrospective study of carmustine or lomustine with bevacizumab in recurrent glioblastoma patients who have failed prior bevacizumab.
Rahman R; Hempfling K; Norden AD; Reardon DA; Nayak L; Rinne ML; Beroukhim R; Doherty L; Ruland S; Rai A; Rifenburg J; LaFrankie D; Alexander BM; Huang RY; Wen PY; Lee EQ
Neuro Oncol; 2014 Nov; 16(11):1523-9. PubMed ID: 24958095
[TBL] [Abstract][Full Text] [Related]
17. Long-term survival of patients with glioblastoma treated with radiotherapy and lomustine plus temozolomide.
Glas M; Happold C; Rieger J; Wiewrodt D; Bähr O; Steinbach JP; Wick W; Kortmann RD; Reifenberger G; Weller M; Herrlinger U
J Clin Oncol; 2009 Mar; 27(8):1257-61. PubMed ID: 19188676
[TBL] [Abstract][Full Text] [Related]
18. Randomized phase II adjuvant factorial study of dose-dense temozolomide alone and in combination with isotretinoin, celecoxib, and/or thalidomide for glioblastoma.
Penas-Prado M; Hess KR; Fisch MJ; Lagrone LW; Groves MD; Levin VA; De Groot JF; Puduvalli VK; Colman H; Volas-Redd G; Giglio P; Conrad CA; Salacz ME; Floyd JD; Loghin ME; Hsu SH; Gonzalez J; Chang EL; Woo SY; Mahajan A; Aldape KD; Yung WK; Gilbert MR; ;
Neuro Oncol; 2015 Feb; 17(2):266-73. PubMed ID: 25239666
[TBL] [Abstract][Full Text] [Related]
19. Continuous low-dose temozolomide and celecoxib in recurrent glioblastoma.
Stockhammer F; Misch M; Koch A; Czabanka M; Plotkin M; Blechschmidt C; Tuettenberg J; Vajkoczy P
J Neurooncol; 2010 Dec; 100(3):407-15. PubMed ID: 20446016
[TBL] [Abstract][Full Text] [Related]
20. Progression-free and overall survival in patients with recurrent Glioblastoma multiforme treated with last-line bevacizumab versus bevacizumab/lomustine.
Heiland DH; Masalha W; Franco P; Machein MR; Weyerbrock A
J Neurooncol; 2016 Feb; 126(3):567-75. PubMed ID: 26614518
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]